TABLE OF CONTENT 1 EXECUTIVE SUMMARY 1.1 OVERVIEW 15 1.1.1 MARKET SYPNOSIS 16 2 MARKET INTRODUCTION 2.1 SCOPE OF THE STUDY 17 2.2 RESEARCH OBJECTIVE 17 2.3 LIST OF ASSUMPTIONS 18 3 RESEARCH METHODOLOGY 3.1 OVERVIEW 19 4 MARKET DYNAMICS 4.1 OVERVIEW 28 4.2 DRIVERS 29 4.2.1 INCREASING PREVALENCE AND INCIDENCE RATE OF ASTHMA AND COPD 29 4.2.2 STRONG PRODUCT PIPELINE 29 4.2.3 RAPIDLY CHANGING LIFESTYLE 29 4.2.4 HIGH R&D EXPENDITURE 29 4.3 RESTRAINTS 30 4.3.1 SIDE EFFECTS AND COMPLICATIONS DURING INHALATION 30 4.3.2 STRINGENT GOVERNMENT REGULATIONS 30 4.4 OPPORTUNITIES 31 4.4.1 INCREASING DEMAND FOR ASTHMA AND COPD DRUGS IN DEVELOPING COUNTRIES 31 5 MARKET FACTOR ANALYSIS 5.1 PORTER’S FIVE FORCES MODEL 32 5.1.1 THREAT OF NEW ENTRANTS 32 5.1.2 BARGAINING POWER OF SUPPLIERS 33 5.1.3 THREAT OF SUBSTITUTES 33 5.1.4 BARGAINING POWER OF BUYERS 33 5.1.5 INTENSITY OF RIVALRY 33 5.2 VALUE CHAIN ANALYSIS 34 5.2.1 R&D AND MANUFACTURING 35 5.2.2 DISTRIBUTION 35 5.2.3 MARKETING & SALES 35 6 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASE 6.1 OVERVIEW 36 6.2 COPD 37 6.3 ASTHMA 37 7 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY PRODUCT 7.1 OVERVIEW 38 7.2 LONG-TERM ASTHMA CONTROL MEDICATIONS 39 7.2.1 COMBINATION DRUGS 40 7.2.2 ANTICHOLINERGICS 43 7.2.3 INHALED CORTICOSTEROIDS 44 7.2.4 LONG-ACTING BETA AGONISTS 47 7.2.5 THEOPHYLLINE 47 7.2.6 OTHERS 48 7.3 QUICK-RELIEF MEDICATIONS 48 7.3.1 SHORT-ACTING BETA AGONISTS 49 7.3.2 ORAL AND INTRAVENOUS CORTICOSTEROIDS 51 7.3.3 IPRATROPIUM BROMIDE (ATROVENT) 51 7.3.4 OTHERS 52 8 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION 8.1 OVERVIEW 53 8.2 ORAL 54 8.3 INHALED 54 8.4 OTHERS (INTRAVENOUS, SUBCUTANEOUS) 55 9 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL 9.1 OVERVIEW 56 9.2 RETAIL PHARMACIES 57 9.3 HOSPITAL PHARMACIES 57 9.4 ONLINE PHARMACIES 58 10 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY REGION 10.1 OVERVIEW 59 10.2 AMERICAS 60 10.2.1 US 64 10.2.2 MEXICO 67 10.2.3 REST OF AMERICAS 71 10.3 EUROPE 75 10.3.1 GERMANY 79 10.3.2 UK 82 10.3.3 RUSSIA 86 10.3.4 REST OF EUROPE 90 10.4 ASIA-PACIFIC 94 10.4.1 CHINA 98 10.4.2 THAILAND 101 10.4.3 REST OF ASIA-PACIFIC 105 10.5 MIDDLE EAST & AFRICA 109 10.5.1 SAUDI ARABIA 113 10.5.2 REST OF MIDDLE EAST & AFRICA 116 11 COMPANY PROFILES 11.1 GLAXOSMITHKLINE PLC 120 11.1.1 COMPANY OVERVIEW 120 11.1.2 FINANCIAL OVERVIEW 121 11.1.3 PRODUCTS/SERVICES OFFERED 122 11.1.4 KEY DEVELOPMENTS 122 11.1.5 SWOT ANALYSIS 123 11.1.6 KEY STRATEGIES 123 11.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 124 11.2.1 COMPANY OVERVIEW 124 11.2.2 FINANCIAL OVERVIEW 124 11.2.3 PRODUCTS/SERVICES OFFERED 125 11.2.4 KEY DEVELOPMENTS 125 11.2.5 SWOT ANALYSIS 126 11.2.6 KEY STRATEGIES 126 11.3 ASTRAZENECA 127 11.3.1 COMPANY OVERVIEW 127 11.3.2 FINANCIAL OVERVIEW 127 11.3.3 PRODUCTS/SERVICES OFFERED 128 11.3.4 KEY DEVELOPMENTS 128 11.3.5 SWOT ANALYSIS 129 11.3.6 KEY STRATEGIES 129 11.4 CHIESI FARMACEUTICI SPA 130 11.4.1 COMPANY OVERVIEW 130 11.4.2 FINANCIAL OVERVIEW 130 11.4.3 PRODUCTS/SERVICES OFFERED 131 11.4.4 KEY DEVELOPMENTS 131 11.4.5 SWOT ANALYSIS 131 11.4.6 KEY STRATEGIES 132 12 APPENDIX 12.1 REFERENCES 133 12.2 RELATED REPORTS 134

LIST OF TABLES TABLE 1 LIST OF ASSUMPTIONS 18 TABLE 2 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASE 2018-2025 (USD MILLION) 36 TABLE 3 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR MEDIUMTHROUGHPUT, BY REGION 2018-2025 (USD MILLION) 37 TABLE 4 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR ASTHMA, BY REGION 2018-2025 (USD MILLION) 37 TABLE 5 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY PRODUCT 2018-2025 (USD MILLION) 38 TABLE 6 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY TYPE 2018-2025 (USD MILLION) 39 TABLE 7 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY REGION 2018-2025 (USD MILLION) 39 TABLE 8 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 40 TABLE 9 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY REGION 2018-2025 (USD MILLION) 40 TABLE 10 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR SERETIDE/ADVAIR, BY REGION 2018-2025 (USD MILLION) 41 TABLE 11 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR SYMBICORT, BY REGION 2018-2025 (USD MILLION) 41 TABLE 12 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR RELVAR/BREO ELLIPTA, BY REGION 2018-2025 (USD MILLION) 41 TABLE 13 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR FLUTIFORM, BY REGION 2018-2025 (USD MILLION) 42 TABLE 14 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR DULERA, BY REGION 2018-2025 (USD MILLION) 42 TABLE 15 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR OTHERS, BY REGION 2018-2025 (USD MILLION) 42 TABLE 16 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 43 TABLE 17 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY REGION 2018-2025 (USD MILLION) 43 TABLE 18 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR SPIRIVA, BY REGION 2018-2025 (USD MILLION) 43 TABLE 19 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR OTHERS, BY REGION 2018-2025 (USD MILLION) 44 TABLE 20 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 44 TABLE 21 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY REGION 2018-2025 (USD MILLION) 45 TABLE 22 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR PULMICORT, BY REGION 2018-2025 (USD MILLION) 45 TABLE 23 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR FLOVENT, BY REGION 2018-2025 (USD MILLION) 45 TABLE 24 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR QVAR, BY REGION 2018-2025 (USD MILLION) 46 TABLE 25 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR OTHERS, BY REGION 2018-2025 (USD MILLION) 46 TABLE 26 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR LONG-ACTING BETA AGONISTS, BY REGION 2018-2025 (USD MILLION) 47 TABLE 27 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR THEOPHYLLINE, BY REGION 2018-2025 (USD MILLION) 47 TABLE 28 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR THEOPHYLLINE, BY REGION 2018-2025 (USD MILLION) 48 TABLE 29 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY TYPE 2018-2025 (USD MILLION) 48 TABLE 30 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY REGION 2018-2025 (USD MILLION) 49 TABLE 31 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 49 TABLE 32 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY REGION 2018-2025 (USD MILLION) 50 TABLE 33 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR PROAIR, BY REGION 2018-2025 (USD MILLION) 50 TABLE 34 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR VENTOLIN, BY REGION 2018-2025 (USD MILLION) 50 TABLE 35 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR ORAL AND INTRAVENOUS CORTICOSTEROIDS, BY REGION 2018-2025 (USD MILLION) 51 TABLE 36 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR IPRATROPIUM BROMIDE (ATROVENT), BY REGION 2018-2025 (USD MILLION) 51 TABLE 37 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR OTHERS, BY REGION 2018-2025 (USD MILLION) 52 TABLE 38 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION 2018-2025 (USD MILLION) 53 TABLE 39 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR ORAL, BY REGION 2018-2025 (USD MILLION) 54 TABLE 40 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR INHALED, BY REGION 2018-2025 (USD MILLION) 54 TABLE 41 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR OTHERS (INTRAVENOUS, SUBCUTANEOUS), BY REGION 2018-2025 (USD MILLION) 55 TABLE 42 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL 2018-2025 (USD MILLION) 56 TABLE 43 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR RETAIL PHARMACIES, BY REGION 2018-2025 (USD MILLION) 57 TABLE 44 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR HOSPITAL PHARMACIES, BY REGION 2018-2025 (USD MILLION) 57 TABLE 45 GLOBAL ASTHMA AND COPD DRUGS MARKET, FOR ONLINE PHARMACIES, BY REGION 2018-2025 (USD MILLION) 58 TABLE 46 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY REGION 2018–2025 (USD MILLION) 59 TABLE 48 AMERICAS: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 60 TABLE 49 AMERICAS: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 61 TABLE 50 AMERICAS: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 61 TABLE 51 AMERICAS: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 61 TABLE 52 AMERICAS: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 62 TABLE 53 AMERICAS: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 62 TABLE 54 AMERICAS: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 62 TABLE 55 AMERICAS: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 63 TABLE 56 AMERICAS: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 63 TABLE 57 AMERICAS: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 63 TABLE 58 AMERICAS: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 64 TABLE 59 US: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 64 TABLE 60 US: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 64 TABLE 61 US: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 65 TABLE 62 US: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 65 TABLE 63 US: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 65 TABLE 64 US: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 66 TABLE 65 US: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 66 TABLE 66 US: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 66 TABLE 67 US: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 67 TABLE 68 US: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 67 TABLE 69 MEXICO: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 67 TABLE 70 MEXICO: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 68 TABLE 71 MEXICO: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 68 TABLE 72 MEXICO: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 68 TABLE 73 MEXICO: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 69 TABLE 74 MEXICO: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 69 TABLE 75 MEXICO: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 69 TABLE 76 MEXICO: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 70 TABLE 77 MEXICO: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 70 TABLE 78 MEXICO: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 70 TABLE 79 REST OF AMERICAS: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 71 TABLE 80 REST OF AMERICAS: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 71 TABLE 81 REST OF AMERICAS: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 71 TABLE 82 REST OF AMERICAS: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 72 TABLE 83 REST OF AMERICAS: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 72 TABLE 84 REST OF AMERICAS: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 72 TABLE 85 REST OF AMERICAS: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 73 TABLE 86 REST OF AMERICAS: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 73 TABLE 87 REST OF AMERICAS: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 73 TABLE 88 REST OF AMERICAS: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 74 TABLE 89 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 75 TABLE 90 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 76 TABLE 91 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 76 TABLE 92 EUROPE: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 76 TABLE 93 EUROPE: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 77 TABLE 94 EUROPE: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 77 TABLE 95 EUROPE: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 77 TABLE 96 EUROPE: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 78 TABLE 97 EUROPE: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 78 TABLE 98 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 78 TABLE 99 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 79 TABLE 100 GERMANY: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 79 TABLE 101 GERMANY: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 79 TABLE 102 GERMANY: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 80 TABLE 103 GERMANY: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 80 TABLE 104 GERMANY: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 80 TABLE 105 GERMANY: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 81 TABLE 106 GERMANY: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 81 TABLE 107 GERMANY: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 81 TABLE 108 GERMANY: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 82 TABLE 109 GERMANY: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 82 TABLE 110 UK: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 82 TABLE 111 UK: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 83 TABLE 112 UK: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 83 TABLE 113 UK: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 83 TABLE 114 UK: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 84 TABLE 115 UK: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 84 TABLE 116 UK: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 85 TABLE 117 UK: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 85 TABLE 118 UK: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 86 TABLE 119 UK: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 86 TABLE 120 RUSSIA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 86 TABLE 121 RUSSIA: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 87 TABLE 122 RUSSIA: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 87 TABLE 123 RUSSIA: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 87 TABLE 124 RUSSIA: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 88 TABLE 125 RUSSIA: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 88 TABLE 126 RUSSIA: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 88 TABLE 127 RUSSIA: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 89 TABLE 128 RUSSIA: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 89 TABLE 129 RUSSIA: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 89 TABLE 130 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 90 TABLE 131 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 90 TABLE 132 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 90 TABLE 133 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 91 TABLE 134 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 91 TABLE 135 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 91 TABLE 136 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 92 TABLE 137 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 92 TABLE 138 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 92 TABLE 139 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 93 TABLE 140 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 94 TABLE 141 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 95 TABLE 142 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 95 TABLE 143 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 95 TABLE 144 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 96 TABLE 145 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 96 TABLE 146 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 96 TABLE 147 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 97 TABLE 148 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 97 TABLE 149 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 97 TABLE 150 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 98 TABLE 151 CHINA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 98 TABLE 152 CHINA: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 98 TABLE 153 CHINA: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 99 TABLE 154 CHINA: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 99 TABLE 155 CHINA: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 99 TABLE 156 CHINA: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 100 TABLE 157 CHINA: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 100 TABLE 158 CHINA: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 100 TABLE 159 CHINA: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 101 TABLE 160 CHINA: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 101 TABLE 161 THAILAND: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 101 TABLE 162 THAILAND: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 102 TABLE 163 THAILAND: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 102 TABLE 164 THAILAND: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 102 TABLE 165 THAILAND: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 103 TABLE 166 THAILAND: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 103 TABLE 167 THAILAND: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 103 TABLE 168 THAILAND: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 104 TABLE 169 THAILAND: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 104 TABLE 170 THAILAND: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 104 TABLE 171 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 105 TABLE 172 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 105 TABLE 173 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 105 TABLE 174 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 106 TABLE 175 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 106 TABLE 176 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 106 TABLE 177 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 107 TABLE 178 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 107 TABLE 179 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 107 TABLE 180 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 108 TABLE 181 MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 109 TABLE 182 MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 109 TABLE 183 MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 110 TABLE 184 MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 110 TABLE 185 MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 110 TABLE 186 MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 111 TABLE 187 MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 111 TABLE 188 MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 111 TABLE 189 MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 112 TABLE 190 MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 112 TABLE 191 MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, BY DSTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 112 TABLE 192 SAUDI ARABIA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 113 TABLE 193 SAUDI ARABIA: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 113 TABLE 194 SAUDI ARABIA: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 113 TABLE 195 SAUDI ARABIA: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 114 TABLE 196 SAUDI ARABIA: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 114 TABLE 197 SAUDI ARABIA: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 114 TABLE 198 SAUDI ARABIA: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 115 TABLE 199 SAUDI ARABIA: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 115 TABLE 200 SAUDI ARABIA: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 115 TABLE 201 SAUDI ARABIA: ASTHMA AND COPD DRUGS MARKET, BY DSTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 116 TABLE 202 REST OF MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2018–2025 (USD MILLION) 116 TABLE 203 REST OF MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 116 TABLE 204 REST OF MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, FOR LONG-TERM ASTHMA CONTROL MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 117 TABLE 205 REST OF MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, FOR COMBINATION DRUGS, BY TYPE 2018-2025 (USD MILLION) 117 TABLE 206 REST OF MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, FOR ANTICHOLINERGICS, BY TYPE 2018-2025 (USD MILLION) 118 TABLE 207 REST OF MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, FOR INHALED CORTICOSTEROIDS, BY TYPE 2018-2025 (USD MILLION) 118 TABLE 208 REST OF MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, FOR QUICK-RELIEF MEDICATIONS, BY PRODUCT 2018-2025 (USD MILLION) 118 TABLE 209 REST OF MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, FOR SHORT-ACTING BETA AGONISTS, BY TYPE 2018-2025 (USD MILLION) 119 TABLE 210 REST OF MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2025 (USD MILLION) 119 TABLE 211 REST OF MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET, BY DSTRIBUTION CHANNEL, 2018–2025 (USD MILLION) 119 TABLE 212 GLAXOSMITHKLINE PLC: PRODUCTS/SERVICES OFFERED 122 TABLE 213 GLAXOSMITHKLINE PLC.: KEY DEVELOPMENTS 122 TABLE 214 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS/SERVICES OFFERED 125 TABLE 215 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY DEVELOPMENTS 125 TABLE 216 ASTRAZENECA: PRODUCTS/SERVICES OFFERED 128 TABLE 217 ASTRAZENECA: KEY DEVELOPMENTS 128 TABLE 218 CHIESI FARMACEUTICI SPA: PRODUCTS/SERVICES OFFERED 131 TABLE 219 CHIESI FARMACEUTICI SPA: KEY DEVELOPMENTS 131LIST OF FIGURES FIGURE 1 GLOBAL ASTHMA AND COPD DRUGS: MARKET STRUCTURE 18 FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 25 FIGURE 3 MARKET DYNAMICS: GLOBAL ASTHMA & COPD DRUGS MARKET 28 FIGURE 4 DRIVERS: IMPACT ANALYSIS 30 FIGURE 5 RESTRAINT IMPACT ANALYSIS 31 FIGURE 6 PORTER’S FIVE FORCES ANALYSIS: GLOBAL ASTHMA AND COPD DRUG MARKET 32 FIGURE 7 VALUE CHAIN ANALYSIS OF THE GLOBAL ASTHMA AND COPD DRUG MARKET 34 FIGURE 8 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASE 2018 & 2025 (USD MILLION) 36 FIGURE 9 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY PRODUCT 2018 & 2025 (USD MILLION) 38 FIGURE 10 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY ROUTE OF ADMINISTRATION 2018 & 2025 (USD MILLION) 53 FIGURE 11 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL 2018 & 20256(USD MILLION) 56 FIGURE 12 GLOBAL ASTHMA AND COPD DRUGS MARKET SHARE, BY REGION 2018 & 2025 (USD MILLION) 59 FIGURE 13 AMERICAS: ASTHMA AND COPD DRUGS MARKET SHARE, BY COUNTRY, 2018 (%) 60 FIGURE 14 EUROPE ASTHMA AND COPD DRUGS MARKET SHARE, BY COUNTRY 2018 (%) 75 FIGURE 15 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET SHARE, BY COUNTRY, 2018 (%) 94 FIGURE 16 MIDDLE EAST & AFRICA: ASTHMA AND COPD DRUGS MARKET SHARE, BY REGION, 2018 (%) 109 FIGURE 17 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 121 FIGURE 18 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 123 FIGURE 19 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT 124 FIGURE 20 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SWOT ANALYSIS 126 FIGURE 21 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 127 FIGURE 22 ASTRAZENECA: SWOT ANALYSIS 129 FIGURE 23 CHIESI FARMACEUTICI SPA: FINANCIAL OVERVIEW SNAPSHOT 130 FIGURE 24 CHIESI FARMACEUTICI SPA: SWOT ANALYSIS 131

GlaxoSmithKline plc (UK), AstraZeneca (UK), Boehringer Ingelheim International GmbH (Germany), and Chiesi Farmaceutici SpA (Italy)